Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240027/S007

SpineSeal Spine Sealant

Pramand, LLC · Decision date Sep 11, 2026

MEDTECHLEDGER EXPLANATIONP240027/S007

What did the FDA approve?

The FDA recorded approval of supplement P240027/S007 for SpineSeal™ Spine Sealant, sponsored by Pramand, LLC, on 2026-09-11. The supplement is classified as a real-time process change with the reason Change Design/Components/Specifications/Material. The recorded scope is a decrease in the lower specification limit for product swelling. This action amends the existing PMA rather than constituting a new approval of the whole sealant system.

The device falls under the dural sealant category, product code NQR, with neurology listed as the specialty. The source record does not include the prior specification value, the revised limit, supporting test data, or the supplement documents, so the magnitude and basis of the change remain unknown. No clinical or performance conclusions about the product follow from this record alone.

FDA approval order statement

Approval to decrease the lower specification limit for product swelling.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Neurology
Decision date
Sep 11, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P240027/S007
Regulatory pathway
PMA supplement
Applicant
Pramand, LLC
Product code
NQR
Decision code
APPR
Decision date
Sep 11, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Sealant, dural.

Applicant
Pramand, LLC
Product code
NQR
FDA device class
3

For the original device and its historical approval scope, see PMA P240027. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240027 · Original PMA

    SpineSeal Spine Sealant

  2. P240027/S007 received

    Application receipt date recorded by FDA.

  3. P240027/S007 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P240027. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240027

Product / regulatory recordCompanyPathwayDecision dateSource
Pramand, LLCPMA approvalFeb 14, 2025FDA

Explore the linked device profile

Other records with product code NQR

Product / regulatory recordCompanyPathwayDecision dateSource
Pramand, LLCPMA supplementOct 1, 2026FDA
Pramand, LLCPMA approvalJul 6, 2023FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Pramand, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
201 Burlington Rd., Suite 210, Bedford, MA, 02420

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records